Oncology prior authorization at Regence
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
Regence oncology PA at a glance
Regence reviews oncology PA submissions against its medical policy library, with rules drawn primarily from NCCN Clinical Practice Guidelines in Oncology + NCCN Drugs & Biologics Compendium. Regence-specific context: BCBS licensee operating in Oregon, Washington (Clark/Cowlitz counties), Idaho, and Utah (~3.1M members). Subsidiary of Cambia Health Solutions. Prime Therapeutics PBM. Each state's DOI handles complaints for policies issued in that state.
Documentation packet — what to send
- Histologic diagnosis with ICD-10-CM code
- Stage at diagnosis + current line of therapy
- Biomarker test result with date and lab
- Prior systemic therapies tried, response, and reason for discontinuation
- Performance status (ECOG or KPS)
- NCCN-supported indication with version number
Common denial patterns to pre-empt
Patterns observed in oncology across payers, and where Regence's book of business overlaps:
- Off-label use not in FDA label
- Step therapy on biosimilar before reference biologic
- Site-of-care reduction (home infusion vs hospital)
- Frequency or duration outside policy
- Companion diagnostic not documented (HER2, PD-L1, MSI, BRCA, etc.)
- Step therapy via Prime Therapeutics
Appeal angles when Regence denies
- NCCN Compendium Category 1/2A citation for off-label support
- Pivotal trial citation by name with FDA approval date
- Genomic biomarker documentation (FoundationOne, Guardant360, MSK-IMPACT)
- Tumor board recommendation
Peer-to-peer prep
- Have the NCCN page reference open on screen (version + page #)
- Open the patient's biomarker report alongside the chart
- Lead with the FDA-approved indication; pivot to NCCN if at the edge of the label
- State the line of therapy explicitly (1L, 2L, 3L) — common point of P2P misunderstanding
Drug-specific PA criteria at Regence
Deep dives on each drug's PA criteria at Regence:
Frequently asked questions
What documentation does Regence need for oncology prior authorizations?
Regence's PA packet for oncology typically includes: Histologic diagnosis with ICD-10-CM code; Stage at diagnosis + current line of therapy; Biomarker test result with date and lab; Prior systemic therapies tried, response, and reason for discontinuation. NCCN Clinical Practice Guidelines in Oncology + NCCN Drugs & Biologics Compendium citations strengthen the submission.
What's the turnaround at Regence?
Regence standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Internal appeal window if denied: 180 days.
Which oncology drugs does Regence most often PA-restrict?
Top targets in oncology: pembrolizumab, rituximab, trastuzumab, bevacizumab, nivolumab. Each follows the per-drug step therapy + documentation requirements published in Regence's medical policy library.
How do I prep a peer-to-peer with Regence in oncology?
Have the NCCN page reference open on screen (version + page #) Open the patient's biomarker report alongside the chart Have the policy URL and the patient's chart open before the call.
Generate a Oncology PA packet
Open ApprovalHelp — generate a oncology PA packet tailored to Regence's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com